Verastem
Yahoo Finance • 2 years ago
Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BOSTON, June 15, 2023--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common st... Full story
Yahoo Finance • 2 years ago
Verastem Stock Is Outperforming 92% Of The Market — And It Just Surged
Verastem could be angling for an accelerated approval of its ovarian cancer treatment, an analyst said Thursday as she upgraded VSTM stock.... Full story
Yahoo Finance • 2 years ago
Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
BOSTON, April 18, 2023--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will present at the Stifel 2023 Virtual... Full story
Yahoo Finance • 2 years ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 06, 2023--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 17,000 shares of it... Full story
Yahoo Finance • 2 years ago
Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
Positive Interim Data Read-Out of RAMP 201 and Productive FDA Meeting Support Avutometinib + Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) Studies of Avutometinib Combinations in Other RAS Pathway-Driven Canc... Full story
Yahoo Finance • 3 years ago
Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
Enrollment Completed in Selection Phases (Part A) of RAMP 201 and RAMP 202 Evaluating VS-6766 +/- Defactinib for the Treatment of Low-Grade Serous Ovarian Cancer and KRAS G12V Mutant Non-Small Cell Lung Cancer Company Secured up to $150 M... Full story
